Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or Lymphoma - Related Studies

Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or Lymphoma

This study has been completed.

Study NCT00631579. Last updated on August 13, 2008. Information provided by Sanofi-Aventis

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Hyperuricemia
		Leukemia
		Lymphoma

2	More general conditions related to this trial
		Immune System Diseases
		Immunoproliferative Disorders
		Lymphatic Diseases
		Lymphoproliferative Disorders
		Neoplasms
		Neoplasms by Histologic Type
		Pathologic Processes

3	Interventions listed in this trial
		Rasburicase (SR29142)

4	Additional drug interventions recognized in this trial
		Rasburicase

5	More general drug interventions related to this trial
		Antirheumatic Agents
		Gout Suppressants
		Pharmacologic Actions
		Therapeutic Uses

6	Sponsors listed in this trial
		Sanofi-Aventis